11/10/2022 9:08:49 AM
Nektar Presents Preclinical Data From Novel PEGylated Interferon Gamma Program, NKTR-288
11/3/2022 4:20:39 PM
Nektar Therapeutics Q3 Loss/share $0.31 Vs. Loss $0.70 Year Ago
8/16/2022 8:35:51 AM
Nektar : Publication Of Preclinical Data For NKTR-255& Observed Improvement Of NK Cell Function In Multiple Myeloma
8/4/2022 4:21:50 PM
Nektar Therapeutics Q2 Loss/share $0.85 Vs. Loss $0.69 Year Ago
7/1/2022 6:31:59 AM
Nektar Promotes Jillian Thomsen To SVP And CFO
5/5/2022 4:17:23 PM
Nektar Therapeutics Q1 Loss/share $0.49 Vs. Loss $0.68 Year Ago
4/14/2022 5:05:28 PM
Nektar, Bristol Myers Announce Update On Clinical Development Program For Bempegaldesleukin In Combination With Opdivo
2/28/2022 4:21:19 PM
Nektar Therapeutics Q4 Loss/share $0.79 Vs. Loss $0.65 Year Ago